

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Jim A. Wright, et al.

Serial No. 08/886,313

Group Art Unit: 1801

Filed: 6/30/97

Examiner:

RECEIVED

JUN 2 1998

For: INHIBITING NEOPLASTIC CELLS UTILIZING THE RIBONUCLEOTIDE REDUCTASE UTR

**CERTIFICATION FOR INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This certification is being made for the Information Disclosure Statement

X accompanying this certification


— filed \_\_\_\_\_

I, the person signing below certify

X that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application.

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail addressed to: the Assistant Commissioner for Patents, Washington, D.C. 20231, May 22, 1998.

  
Karla M. Ashfield

U.S.S.N. 08/886,313

AND

X that no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the statement.

The person making this certification is the attorney


who signs below on the basis of:

- the information supplied by the inventor(s)
- X the information supplied by an individual designated in § 1.56(c)
- X the information in the attorney's file

The Commissioner is authorized to charge any fee or credit any overpayment in connection with this communication to our Deposit Account No. 11-1449.

Respectfully submitted,

KOHN & ASSOCIATES

  
Ilene N. Montgomery  
Registration No. 38,972  
30500 Northwestern Hwy.  
Ste. 410  
Farmington Hills, MI 48334  
(248) 539-5050  
Date: May 22, 1998



Practitioner's Docket No. 0227.00003

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

JUN 2 1998

In re application of: Jim A. Wright, et al.

Serial Number: 08/886,313

Group Art Unit: 1801

Filed: 6/30/97

Examiner:

For: INHIBITING NEOPLASTIC CELLS UTILIZING THE RIBONUCLEOTIDE  
REDUCTASE UTR

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR 1.97(e)(1)**

Box DD  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Provided herewith are copies of patents and publications as listed in the attached PTO-1449 (supplemental).


While the statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such. The filing of this statement does not mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

U.S.S.N. 08/886,313

Please charge our Deposit Account No. 11-1449 for any additional fees or credit our account for any overpayment. **A duplicate of this transmittal is attached.**

Respectfully submitted,

KOHN & ASSOCIATES


  
Ilene N. Montgomery  
Registration No. 38,972  
30500 Northwestern Hwy.  
Suite 410  
Farmington Hills, MI 48334  
(248) 539-5050

Date: May 22, 1998


---

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on May 22, 1998.

  
Karla M. Ashfield

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number :	08/886,313
		Filing Date:	6/30/97
		First Named Inventor:	Jim A. Wright
		Group Art Unit:	1801
		Examiner Name:	
Sheet 1 of 3	Attorney Docket Number:	0227.00003	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

RECEIVED

JUN 2 1998

MAILED 06/02/98  
SERIALIZED 06/02/98

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup> (if known)				

EP 0 383 190 A2	Bio-Mega Inc.	08/22/90
EP 0 726 277 A2	Kyowa Hakko Kogyo Co., Ltd.	08/14/96
WO 93/17125	Baylor College of Medicine Isis Pharmaceuticals, Inc.	09/02/93

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number :	08/886,313
		Filing Date:	6/30/97
		First Named Inventor:	Jim A. Wright
		Group Art Unit:	1801 JUN 2 1998
		Examiner Name:	
Sheet 2 of 3	Attorney Docket Number:	022700003	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.
		T2

AMARA, F.M., ET AL., Altered Regulation of Message Stability and Tumor Promoter-responsive *cis-trans* Interactions of Ribonucleotide Reductase R1 and R2 Messenger RNAs in Hydroxyurea-resistant Cells, Cancer Research, 55:4503-4506, 1995.

AMARA, F.M., ET AL., A novel transforming growth factor-beta responsive cytoplasmic trans-acting factor binds selectively to the 3'-untranslated region of mammalian ribonucleotide reductase R2 mRNA: role in message stability, Nucleic Acids Research, 21:4803-4809, 1993.

ALTSCHUL, S.F., ET AL., Basic Local Alignment Search Tool, 403-410, 1990.

CHEN, F.Y., ET AL., Mammalian ribonucleotide reductase R1 mRNA stability under normal and phorbol ester stimulating conditions: involvement of a *cis-trans* interaction at the 3' untranslated region, The EMBO Journal, 12(10):3977-3986, 1993.

CREGG, J.M., ET AL., Recent Advances in the Expression of Foreign Genes in *Pichia pastoris*, Bio/Technology, 11:905-910, 1993.

FAN, H., ET AL., Suppression of Malignancy by the 3' Untranslated Regions of Ribonucleotide Reductase R1 and R2 Messenger RNAs, Cancer Research, 56:4366-4369, 1996.

GREENE, L.A., ET AL., Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor, Proc. Natl. Acad. Sci. USA, 73(7):2424-2428, 1976.

GUBLER U. AND HOFFMAN, B.J., A simple and very efficient method for generating cDNA libraries, Gene, 25:263-269, 1983.

PARKER, N.J., ET AL., Human M1 subunit of ribonucleotide reductase: cDNA sequence and expression in stimulated lymphocytes, Nucleic Acids Research, 19(13):3741, 1991.

PAVLOFF, N., ET AL., Sequence analysis of the large and small subunits of human ribonucleotide reductase, DNA Sequence, 2:227-234, 1992.

EMBL/GenBank/DDBJ Databases, Accession number no. aa452273, Unpublished, created June 11, 1997, HILLIER, ET AL., "WashU-Merck Est Project 1997", XP002048834

EMBL/GenBank/DDBJ Databases, Accession number no. g07100, Unpublished, created June 15, 1995, HUDSON, ET AL., "The Whitehead Institute/MIT Center for Genome Research; Physically mapped ESTs", XP002048239

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.